Does this have any FDA approvals?
No. Plus they are currently focusing on TDT and SCD, both early stage, and both indications becoming more crowed. Also, CRSP should get FDA and EMA approvals for exa-cel in those indications and should have at least five years head start over others.
Will Precision Biosciences be this high or higher?
If the clinical data they present in April/May is good, I expect the SP will increase, but not as high as this. They (DTIL) will also have an upcoming R&D Day (focusing on in vivo programs) mid-year.
How do the two compare?
There are a number of differences. One example, DTIL have yet to show they can do in vivo editing in humans. Another, both have broad plans for in vivo programs, but delivery outside the liver (using current AAVs for many indications) can be problematic.
Recent EDIT News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 10:04:37 AM
- Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress • GlobeNewswire Inc. • 06/14/2024 07:01:00 AM
- Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress • GlobeNewswire Inc. • 06/14/2024 07:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:17:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:16:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 09:15:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 09:13:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:30:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:27:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:25:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/31/2024 08:21:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/31/2024 08:20:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:18:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:30:13 PM
- Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting • GlobeNewswire Inc. • 05/10/2024 10:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:21:43 PM
- U.S. Futures Slightly Dip Amid Corporate Earnings and Quiet Economic Calendar, Oil Prices Fall • IH Market News • 05/08/2024 12:29:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 11:08:48 AM
- Editas Medicine Announces First Quarter 2024 Results and Business Updates • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting • GlobeNewswire Inc. • 04/22/2024 08:31:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:06:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:03:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 01:00:16 AM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM